PDCD1 and Meckel syndrome, type 1: Since the GET score is correlated with better clinical benefit for ICI agents (50), MES may have a positive effect on the immunotherapy response, which is further confirmed by SubMap analysis, which shows that MES patients are more likely to benefit from anti-PD1 treatment.